Antifungal azoles: Structural insights into undesired tight binding to cholesterol-metabolizing cyp46a1s

Molecular Pharmacology

Volumn 84, Issue 1, 2013, Pages 86-94

  Mast, Natalia ^a   Zheng, Wenchao ^a   Stout, C David ^b   Pikuleva, Irina A ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBACONAZOLE; ANTIFUNGAL AGENT; BIFONAZOLE; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 46A1; ECONAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LIGAND; NITROGEN; POSACONAZOLE; PYRROLE DERIVATIVE; QUINAZOLINE; RAVUCONAZOLE; STEROL 14ALPHA DEMETHYLASE; TRIAZOLE; UNCLASSIFIED DRUG; VORICONAZOLE;

ARTICLE; ATOM; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; SURFACE PROPERTY;

ANTIFUNGAL AGENTS; AZOLES; BINDING SITES; CHOLESTEROL; CLOTRIMAZOLE; CRYSTALLOGRAPHY, X-RAY; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PROTEIN BINDING; PYRIMIDINES; STEROID HYDROXYLASES; STEROL 14-DEMETHYLASE; TRIAZOLES;

EID: 84879070955     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.085902     Document Type: Article

References (34)

1. Arnold TM, Dotson E, Sarosi GA, and Hage CA (2010) Traditional and emerging antifungal therapies. Proc Am Thorac Soc 7:222-228
2. Björkhem I, Lütjohann D, Breuer O, Sakinis A, and Wennmalm A (1997) Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J Biol Chem 272:30178-30184.
3. Chen CK, Leung SS, Guilbert C, Jacobson MP, McKerrow JH, and Podust LM (2010) Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Negl Trop Dis 4:e651.
4. Collaborative Computational Project, Number 4 (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50:760-763.
5. Ekroos M and Sjögren T (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc Natl Acad Sci USA 103:13682-13687.
6. Emsley P and Cowtan K (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60:2126-2132.
7. Girmenia C (2009) New generation azole antifungals in clinical investigation. Expert Opin Investig Drugs 18:1279-1295.
8. Guengerich FP(2005) Human cytochrome P450 enzymes, in Cytochrome P450 (Ortiz de Montellano PR ed) pp 377-530, Kluwer Academic/Plenum, New York.
9. Hargrove TY, Wawrzak Z, Liu J, Nes WD, Waterman MR, and Lepesheva GI (2011) Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14a-demethylase (CYP51) from Leishmania infantum. J Biol Chem 286:26838-26848
10. Kabsch W (2010) Xds. Acta Crystallogr D Biol Crystallogr 66:125-132.
11. Katragkou A, Tsikopoulou F, Roilides E, and Zaoutis TE (2012) Posaconazole: when and how? The clinician's view. Mycoses 55:110-122.
12. Lepesheva GI, Hargrove TY, Anderson S, Kleshchenko Y, Furtak V, Wawrzak Z, Villalta F, and Waterman MR (2010) Structural insights into inhibition of sterol 14a-demethylase in the human pathogen Trypanosoma cruzi. J Biol Chem 285: 25582-25590.
13. Lepesheva GI and Waterman MR (2007) Sterol 14a-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms. Biochim Biophys Acta 1770:467-477
14. Lepesheva GI and Waterman MR (2011) Structural basis for conservation in the CYP51 family. Biochim Biophys Acta 1814:88-93.
15. Lipp HP (2010) Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. Br J Clin Pharmacol 70: 471-480.
16. Lund EG, Xie C, Kotti T, Turley SD, Dietschy JM, and Russell DW (2003) Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J Biol Chem 278:22980-22988
17. Maertens JA (2004) History of the development of azole derivatives. Clin Microbiol Infect 10 (Suppl 1):1-10.
18. Mast N, Andersson U, Nakayama K, Bjorkhem I, and Pikuleva IA (2004) Expression of human cytochrome P450 46A1 in Escherichia coli: effects of N-And C-terminal modifications. Arch Biochem Biophys 428:99-108
19. Mast N, Annalora AJ, Lodowski DT, Palczewski K, Stout CD, and Pikuleva IA (2011) Structural basis for three-step sequential catalysis by the cholesterol side chain cleavage enzyme CYP11A1. J Biol Chem 286:5607-5613.
20. Mast N, Charvet C, Pikuleva IA, and Stout CD (2010) Structural basis of drug binding to CYP46A1, an enzyme that controls cholesterol turnover in the brain. J Biol Chem 285:31783-31795.
21. Mast N, Linger M, Clark M, Wiseman J, Stout CD, and Pikuleva IA (2012) In silico and intuitive predictions of CYP46A1 inhibition by marketed drugs with subsequent enzyme crystallization in complex with fluvoxamine. Mol Pharmacol 82: 824-834.
22. Mast N, Linger M, and Pikuleva IA (2013a) Inhibition and stimulation of activity of purified recombinant CYP11A1 by therapeutic agents. Mol Cell Endocrinol 371: 100-106.
23. Mast N, White MA, Bjorkhem I, Johnson EF, Stout CD, and Pikuleva IA (2008) Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci USA 105: 9546-9551.
24. Mast N, Zheng W, Stout CD, and Pikuleva IA (2013b) Binding of a cyano-And fluorocontaining drug bicalutamide to cytochrome P450 46A1: unusual features and spectral response. J Biol Chem 288:4613-4624.
25. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, and Read RJ (2007) Phaser crystallographic software. J Appl Cryst 40:658-674.
26. Murshudov GN, Vagin AA, and Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53:240-255.
27. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. J Biol Chem 239:2370-2378
28. Podust LM, Poulos TL, and Waterman MR (2001) Crystal structure of cytochrome P450 14a -sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with azole inhibitors. Proc Natl Acad Sci USA 98:3068-3073.
29. Shafaati M, Mast N, Beck O, Nayef R, Heo GY, Björkhem-Bergman L, Lütjohann D, Björkhem I, and Pikuleva IA (2010) The antifungal drug voriconazole is an efficient inhibitor of brain cholesterol 24S-hydroxylase in vitro and in vivo. J Lipid Res 51: 318-323.
30. Soltis SM, Cohen AE, Deacon A, Eriksson T, González A, McPhillips S, Chui H, Dunten P, Hollenbeck M, and Mathews I et al. (2008) New paradigm for macromolecular crystallography experiments at SSRL: automated crystal screening and remote data collection. Acta Crystallogr D Biol Crystallogr 64:1210-1221.
31. Strushkevich N, MacKenzie F, Cherkesova T, Grabovec I, Usanov S, and Park HW (2011) Structural basis for pregnenolone biosynthesis by the mitochondrial monooxygenase system. Proc Natl Acad Sci USA 108:10139-10143.
32. Strushkevich N, Usanov SA, and Park HW (2010) Structural basis of human CYP51 inhibition by antifungal azoles. J Mol Biol 397:1067-1078
33. White MA, Mast N, Bjorkhem I, Johnson EF, Stout CD, and Pikuleva IA (2008) Use of complementary cation and anion heavy-Atom salt derivatives to solve the structure of cytochrome P450 46A1. Acta Crystallogr D Biol Crystallogr 64: 487-495.
34. White TC, Marr KA, and Bowden RA (1998) Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 11:382-402. Medical Sciences General Medical Sciences